Gynecological Cancer: Diagnosis and Screening

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 31 January 2026 | Viewed by 804

Special Issue Editors


E-Mail Website
Guest Editor
1. Province Chancellor Research Innovation and Business Development, University of Namibia UNAM, Windhoek, Namibia
2. Medicine School, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
Interests: global oncology; cervical cancer; cancer equity
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Medical and Surgical Specialities, Faculty of Medicine, Transylvania University of Brasov, 56 Nicolae Balcescu Street, 500019 Brașov, Romania
Interests: gynecological cancer

Special Issue Information

Dear Colleagues,

This upcoming Special Issue of Pathology and Molecular Diagnostics focuses on the critical topic of gynecological cancer, encompassing cutting-edge advancements in diagnosis and screening. This issue aims to bring together leading research and clinical insights to enhance our understanding and improve outcomes in gynecological oncology.

Gynecological cancers, including cervical, ovarian, uterine, vaginal, and vulvar cancers, pose significant health challenges worldwide. Early and accurate diagnosis, coupled with effective screening programs, is crucial for reducing morbidity and mortality associated with these cancers.

Key themes explored in this Special Issue include the following:

  • Innovative Diagnostic Techniques: exploration of novel imaging technologies, biomarkers, and molecular diagnostics that offer greater accuracy and earlier detection of gynecological cancers.
  • Screening Strategies: evaluation of current screening methods, such as Pap smears and HPV testing, alongside emerging approaches like liquid biopsy and genetic screening.
  • Epidemiological Insights: analysis of global incidence and prevalence patterns, risk factors, and the impact of socio-economic determinants on gynecological cancer outcomes.
  • Personalized Medicine: advances in personalized screening and diagnosis tailored to individual genetic profiles and risk factors, aiming to enhance precision and efficacy.

This Special Issue serves as a comprehensive resource for researchers and clinicians dedicated to advancing the early detection and effective management of gynecological cancers. Through the dissemination of innovative research and practical insights, it aims to contribute to the ongoing efforts to improve women's health worldwide.

Prof. Dr. Daniela-Cristina Stefan
Dr. Marius Alexandru Moga
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynaecological cancers 
  • diagnoses gynecological cancers 
  • screening gynecological cancers
  • global gynecological cancers 
  • cancer equity 
  • innovative approaches to gynecological cancers 
  • gynaecological cancers outcome 
  • global pathology gynecological cancers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2137 KB  
Article
Clinical Evaluation of a Multi-Omic Diagnostic Model for Early-Stage Ovarian Cancer Detection
by Robert A. Law, Brendan M. Giles, Rachel Culp-Hill, Enkhtuya Radnaa, Mattie Goldberg, Charles M. Nichols, Maria Wong, Connor Hansen, Collin Hill, Katrin Eurich, Emily Prendergast, Kian Behbakht, Benjamin G. Bitler, Anna Jeter, Vuna S. Fa, James Robert White, Kevin Elias and Abigail McElhinny
Diagnostics 2025, 15(17), 2225; https://doi.org/10.3390/diagnostics15172225 - 2 Sep 2025
Viewed by 442
Abstract
Background/Objectives: Ovarian cancer (OC) is frequently diagnosed at an advanced stage due to the nonspecific nature of its symptoms. While population-wide screening has failed to reduce mortality, timely diagnosis in symptomatic women remains a promising and underutilized strategy to improve clinical outcomes. [...] Read more.
Background/Objectives: Ovarian cancer (OC) is frequently diagnosed at an advanced stage due to the nonspecific nature of its symptoms. While population-wide screening has failed to reduce mortality, timely diagnosis in symptomatic women remains a promising and underutilized strategy to improve clinical outcomes. The aim of this study was to develop a sensitive, scalable biomarker assay to improve early-stage detection in symptomatic women. Methods: A multi-omic diagnostic model was developed using serum samples from symptomatic women. Lipidomic profiles were generated by liquid chromatography–mass spectrometry (LC-MS), and protein levels were measured using immunoassays. Statistical and machine learning approaches were applied to assess diagnostic performance across disease stages and subtypes. Results: The multi-omic model demonstrated robust performance across a clinically challenging population, with both lipid and protein data necessary for detecting OC across a range of stages and subtypes. The model achieved 98.7% sensitivity in early-stage OC and 98.6% across a range of OC subtypes and stages at 70% fixed specificity, which represented significant improvements over CA125 in the same cohort. In addition, in a small subset of samples, lipid and protein profiles from OC patients undergoing treatment differed from untreated patients and controls, suggesting that this approach may also be useful in other aspects of clinical management, such as treatment monitoring. Conclusions: This multi-omic assay offers a promising solution to accelerate diagnosis, improve early detection, and potentially reduce OC mortality. Full article
(This article belongs to the Special Issue Gynecological Cancer: Diagnosis and Screening)
Show Figures

Figure 1

Back to TopTop